• Molecular NameAcetazolamide
  • SynonymAcetamidothiadiazolesulfonamide; Acetazolamid; Acetazolamide Sodium; Acetazolamine; Acetazoleamide; Acetozalamide; Carbonic Anhydrase Inhibitor 6063
  • Weight222.249
  • Drugbank_IDDB00819
  • ACS_NO1424-27-7
  • Show 3D model
  • LogP (experiment)-0.26
  • LogP (predicted, AB/LogP v2.0)-0.37
  • pka7.2, 9.0
  • LogD (pH=7, predicted)-0.55
  • Solubility (experiment)0.719 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-1.67
  • LogSw (predicted, AB/LogsW2.0)2.0
  • Sw (mg/ml) (predicted, ACD/Labs)2.85
  • No.of HBond Donors3
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds2
  • TPSA151.66
  • StatusFDA approved
  • AdministrationOral, IV
  • PharmacologyA carbonic anhydrase inhibitor that is used to treat glaucoma, epileptic seizures, benign intracranial hypertension (pseudotumor cerebri), altitude sickness, cystinuria, and dural ectasia.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability99.0
  • Protein binding45.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • Metabollsmacetazolamide is excreted unchanged.
  • Half life3~9 h,Plasma half-life, about 13 h; blood and erythrocyte concentrations decrease more slowly
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A